Momentum is continuing for the biotech after an announcement of positive clinical results and buying by key insiders earlier this month.
News & Analysis: Akebia Therapeutics
Insider buying is generating enthusiasm for this biotech stock among investors who aren't insiders.
The biotech's Q3 results weren't anything to crow about. But a big loan agreement will allow Akebia to fund operations until key clinical results are announced.
AKBA earnings call for the period ending September 30, 2019.
AKBA earnings call for the period ending June 30, 2019.
AKBA earnings call for the period ending March 31, 2019.
AKBA earnings call for the period ending December 31, 2018.
Good news on several fronts helped lift many stocks.
Great news from two late-stage studies lit a fire under the biopharmaceutical stock.
Traders cheer after the company completes its merger agreement. Here's what investors need to know.